PDF(Pubmed)
Abstract：
BACKGROUND: In recent decades, all-cause mortality has increased among individuals with chronic kidney disease (CKD), influenced by factors such as aetiology, standards of care and access to kidney replacement therapies (dialysis and transplantation). The recent COVID-19 pandemic also affected mortality over the past few years. Here, we outline the protocol for a systematic review to investigate global temporal trends in all-cause mortality among patients with CKD at any stage from 1990 to current. We also aim to assess temporal trends in the mortality rate associated with the COVID-19 pandemic.
METHODS: We will conduct a systematic review of studies reporting mortality for patients with CKD following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We will search electronic databases, national and multiregional kidney registries and grey literature to identify observational studies that reported on mortality associated with any cause for patients with CKD of all ages with any stage of the disease. We will collect data between April and August 2023 to include all studies published from 1990 to August 2023. There will be no language restriction, and clinical trials will be excluded. Primary outcome will be temporal trends in CKD-related mortality. Secondary outcomes include assessing mortality differences before and during the COVID-19 pandemic, exploring causes of death and examining trends across CKD stages, country classifications, income levels and demographics.
BACKGROUND: A systematic review will analyse existing data from previously published studies and have no direct involvement with patient data. Thus, ethical approval is not required. Our findings will be published in an open-access peer-reviewed journal and presented at scientific conferences.
UNASSIGNED: CRD42023416084.
METHODS: We will conduct a systematic review of studies reporting mortality for patients with CKD following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We will search electronic databases, national and multiregional kidney registries and grey literature to identify observational studies that reported on mortality associated with any cause for patients with CKD of all ages with any stage of the disease. We will collect data between April and August 2023 to include all studies published from 1990 to August 2023. There will be no language restriction, and clinical trials will be excluded. Primary outcome will be temporal trends in CKD-related mortality. Secondary outcomes include assessing mortality differences before and during the COVID-19 pandemic, exploring causes of death and examining trends across CKD stages, country classifications, income levels and demographics.
BACKGROUND: A systematic review will analyse existing data from previously published studies and have no direct involvement with patient data. Thus, ethical approval is not required. Our findings will be published in an open-access peer-reviewed journal and presented at scientific conferences.
UNASSIGNED: CRD42023416084.
摘要：
背景：近几十年来，慢性肾脏病（CKD）患者的全因死亡率增加，受病因等因素的影响，护理标准和获得肾脏替代疗法（透析和移植）。最近的COVID-19大流行也影响了过去几年的死亡率。这里,我们概述了一项系统评价方案,以调查从1990年到目前任何阶段CKD患者全因死亡率的全球时间趋势.我们还旨在评估与COVID-19大流行相关的死亡率的时间趋势。
方法：我们将根据系统评价和Meta分析指南的首选报告项目，对报告CKD患者死亡率的研究进行系统评价。我们将搜索电子数据库，国家和多地区的肾脏登记册和灰色文献，以确定观察性研究，这些研究报告了所有年龄段的CKD患者与任何疾病阶段的任何原因相关的死亡率。我们将收集2023年4月至8月的数据，包括1990年至2023年8月发表的所有研究。不会有语言限制，临床试验将被排除。主要结果将是CKD相关死亡率的时间趋势。次要结果包括评估COVID-19大流行之前和期间的死亡率差异，探索死亡原因并检查CKD阶段的趋势，国家分类，收入水平和人口统计数据。
背景：系统评价将分析先前发表的研究中的现有数据，并且与患者数据没有直接关系。因此，不需要道德批准。我们的研究结果将发表在开放获取同行评审的期刊上，并在科学会议上发表。
■CRD42023416084。
方法：我们将根据系统评价和Meta分析指南的首选报告项目，对报告CKD患者死亡率的研究进行系统评价。我们将搜索电子数据库，国家和多地区的肾脏登记册和灰色文献，以确定观察性研究，这些研究报告了所有年龄段的CKD患者与任何疾病阶段的任何原因相关的死亡率。我们将收集2023年4月至8月的数据，包括1990年至2023年8月发表的所有研究。不会有语言限制，临床试验将被排除。主要结果将是CKD相关死亡率的时间趋势。次要结果包括评估COVID-19大流行之前和期间的死亡率差异，探索死亡原因并检查CKD阶段的趋势，国家分类，收入水平和人口统计数据。
背景：系统评价将分析先前发表的研究中的现有数据，并且与患者数据没有直接关系。因此，不需要道德批准。我们的研究结果将发表在开放获取同行评审的期刊上，并在科学会议上发表。
■CRD42023416084。
